In a nutshell This study is being carried out to examine whether KRD including carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Decadron) with or without daratumumab (Darzalex) is safe and effective in the treatment of multiple myeloma (MM). The main outcome to be measured is the measurable residual...
Read More
In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....
Read More
In a nutshell This trial is being carried out to assess whether osimertinib (Tagrisso) should be used alone or with chemotherapy for lung cancer and abnormalities (mutations) in the EGFR gene. The main outcome that will be measured in this trial is survival without progression of the disease. This trial will take place in New Jersey and New...
Read More
In a nutshell This phase 2 trial is examining the effectiveness of TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) in the treatment of metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured will be the overall response to the treatment rate. This study is being conducted in New Jersey, US. The details...
Read More
In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...
Read More
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with progressive non-Hodgkin lymphoma (NHL). The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details Patients...
Read More
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...
Read More
In a nutshell This phase 2 trial is examining the effectiveness of tumor-infiltrating lymphocytes (TIL) in the treatment of colorectal cancer. The main outcome to be measured is the tumor response to the treatment. This trial will be conducted in Texas, US. The details Cancer is one of the leading causes of death worldwide. Therapy such as...
Read MoreIn a nutshell This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer, or ductal carcinoma in-situ (DCIS). The main outcome that will be measured is if patients experience any side effects. The study is taking place in New Jersey and New York, the United States. The...
Read MoreIn a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read More
In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...
Read MoreIn a nutshell This phase 2 study will investigate the effectiveness of experimental medication tucatinib and trastuzumab (Herceptin) to treat brain metastases in HER2-positive breast cancer (BC). The main outcome will be overall survival (OS). This trial is recruiting in Alabama and Texas, the US. The details...
Read More
